EMPA-REG OUTCOME: The Cardiologist's Point of View

The American Journal of Medicine
Son V Pham, Robert Chilton

Abstract

Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patients with high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to cardiovascular physiology; namely, by the potential ability of empagliflozin to reduce cardiac workload and myocardial oxygen consumption by lowering blood pressure, improving aortic compliance, and improving ventricular arterial coupling. These concepts and hypotheses are discussed in this report.

References

Apr 10, 1995·Archives of Internal Medicine·N R CookC H Hennekens
Dec 12, 2002·Journal of the American College of Cardiology·Tommaso GoriJohn D Parker
May 7, 2004·The New England Journal of Medicine·Michael R ZileWilliam H Gaasch
Mar 4, 2008·Heart Failure Clinics·Barry A Borlaug, David A Kass
Aug 30, 2008·Diabetes Research and Clinical Practice·Osamu YonahaNigishi Hotta
Sep 19, 2008·European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology·Francesco Antonini-CanterinUNKNOWN Research Group of the Italian Society of Cardiovascular Echography (SIEC)
Apr 5, 2012·Nature Reviews. Endocrinology·Bithika Thompson, Dwight A Towler
May 29, 2012·Archives of Cardiovascular Diseases·Laura Ernande, Geneviève Derumeaux
Aug 7, 2014·Archives of Medical Science : AMS·Jacek Kasznicki, Jozef Drzewoski
Oct 2, 2014·Diabetes Care·Ilkka TikkanenUNKNOWN EMPA-REG BP Investigators
Apr 19, 2015·European Heart Journal·Petar M Seferović, Walter J Paulus
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Jan 26, 2016·Current Opinion in Nephrology and Hypertension·Ilkka TikkanenOdd Erik Johansen
May 22, 2016·Diabetes Care·Muhammad Abdul-GhaniRalph A DeFronzo
Dec 3, 2016·Journal of the American Heart Association·Teemu J NiiranenRamachandran S Vasan
Jan 27, 2017·Arteriosclerosis, Thrombosis, and Vascular Biology·Alicia N Lyle, Uwe Raaz
May 21, 2017·The American Journal of Medicine·Christoph Wanner
May 21, 2017·The American Journal of Medicine·Michael Lehrke, Nikolaus Marx

❮ Previous
Next ❯

Citations

Apr 29, 2018·Heart Failure Reviews·Joaquim Silva CustodioLeonardo Roever
Jan 13, 2018·Heart Failure Reviews·Abdullah KaplanFouad A Zouein
Apr 18, 2020·The Journal of Clinical Endocrinology and Metabolism·Nicola FlemingElif I Ekinci
Jun 28, 2018·Drugs·James E Frampton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.